Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F
Pain Therapy and Palliative Care Division, National Cancer Institute, Milan, Italy.
J Clin Oncol. 1998 Oct;16(10):3216-21. doi: 10.1200/JCO.1998.16.10.3216.
To define the dose ratio between morphine and methadone in relation to the previous morphine dose and the number of days needed to achieve the same level of analgesia in a group of patients with advanced cancer with pain who switched from morphine to oral methadone.
A cross-sectional prospective study of 38 consecutive cancer patients who switched from morphine to oral methadone was performed. The intensity of pain before, during, and after the switching period was assessed through a four-point verbal Likert scale. The relationship between previous morphine dose and the final equianalgesic methadone dose, dose ratio between morphine and methadone, and the number of days required to achieve equianalgesia have been examined by means of Pearson's correlation coefficient, scatter plots, and Cuzick's test for trend respectively.
Before the switch, the median oral equivalent daily dose of morphine was 145 mg/d; after the switch, the median equianalgesic oral methadone dose was 21 mg/d. A median time of 3 days (range, 1 to 7 days) was necessary to achieve the equianalgesia with oral methadone; the lower the preswitching morphine dose, the fewer days necessary to achieve equianalgesia with oral methadone (P < .001). Dose ratios ranged from 2.5:1 to 14.3:1 (median, 7.75:1), which indicated that, in most cases, the dose ratio was much higher than that suggested by the published equianalgesic tables. A strong linear positive relationship between morphine and methadone equianalgesic doses was obtained (Pearson's correlation coefficient, 0.91). The dose ratio increased with the increase of the previous morphine dose with a much higher increase at low morphine doses.
The results of our study confirm that methadone is a potent opioid, more potent than believed. Caution is recommended when switching from any opioid to methadone, especially in patients who are tolerant to high doses of opioids.
确定在一组从吗啡转换为口服美沙酮的晚期癌症疼痛患者中,吗啡与美沙酮之间的剂量比与先前吗啡剂量以及达到相同镇痛水平所需天数之间的关系。
对38例连续从吗啡转换为口服美沙酮的癌症患者进行了一项横断面前瞻性研究。通过四点言语Likert量表评估转换期之前、期间和之后的疼痛强度。分别采用Pearson相关系数、散点图和Cuzick趋势检验来研究先前吗啡剂量与最终等效镇痛美沙酮剂量之间的关系、吗啡与美沙酮之间的剂量比以及达到等效镇痛所需的天数。
转换前,吗啡的口服等效日剂量中位数为145 mg/d;转换后,等效镇痛口服美沙酮剂量中位数为21 mg/d。口服美沙酮达到等效镇痛所需的中位时间为3天(范围为1至7天);转换前吗啡剂量越低,口服美沙酮达到等效镇痛所需的天数越少(P <.001)。剂量比范围为2.5:1至14.3:1(中位数为7.75:1),这表明在大多数情况下,剂量比远高于已发表的等效镇痛表所建议的比例。吗啡与美沙酮等效镇痛剂量之间存在强烈的线性正相关关系(Pearson相关系数为0.91)。剂量比随着先前吗啡剂量的增加而增加,在低吗啡剂量时增加幅度更大。
我们的研究结果证实美沙酮是一种强效阿片类药物,比人们认为的更有效。建议在从任何阿片类药物转换为美沙酮时要谨慎,尤其是对高剂量阿片类药物耐受的患者。